|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Dicerna_Pharmaceuticals
gptkb:Emisphere_Technologies
|
|
gptkbp:annualReport
|
https://www.novonordisk.com/investors/annual-report.html
|
|
gptkbp:awards
|
gptkb:Galien_Prize
|
|
gptkbp:CEO
|
gptkb:Lars_Fruergaard_Jørgensen
|
|
gptkbp:country
|
gptkb:Denmark
|
|
gptkbp:division
|
Diabetes and Obesity Care
Rare Disease
|
|
gptkbp:environmentalImpact
|
gptkb:Circular_for_Zero
|
|
gptkbp:focusArea
|
diabetes care
rare diseases
obesity care
|
|
gptkbp:founded
|
1923
|
|
gptkbp:foundedBy
|
gptkb:August_Krogh
gptkb:Marie_Krogh
gptkb:Hans_Christian_Hagedorn
|
|
gptkbp:headquarters_location
|
gptkb:Bagsværd,_Denmark
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Novo Nordisk
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:listedOn
|
gptkb:OMX_Copenhagen_20
gptkb:NASDAQ
|
|
gptkbp:logo
|
gptkb:Apis_bull
|
|
gptkbp:marketCap
|
over $500 billion (2024)
|
|
gptkbp:member
|
gptkb:International_Diabetes_Federation
gptkb:European_Federation_of_Pharmaceutical_Industries_and_Associations
|
|
gptkbp:netIncome
|
83.7 billion DKK (2023)
|
|
gptkbp:number_of_countries_operated_in
|
80+
|
|
gptkbp:numberOfEmployees
|
~55,000 (2023)
|
|
gptkbp:parentOrganization
|
gptkb:Novo_Holdings_A/S
|
|
gptkbp:products
|
gptkb:insulin
gptkb:NovoRapid
gptkb:Ozempic
gptkb:Rybelsus
gptkb:Victoza
gptkb:Wegovy
|
|
gptkbp:R&D_locations
|
gptkb:China
gptkb:Denmark
gptkb:India
gptkb:United_States
|
|
gptkbp:revenue
|
232.3 billion DKK (2023)
|
|
gptkbp:stockExchange
|
gptkb:Copenhagen_Stock_Exchange
|
|
gptkbp:stockSymbol
|
gptkb:NOVO-B
gptkb:NVO
|
|
gptkbp:subsidiary
|
gptkb:Novo_Nordisk_Foundation
|
|
gptkbp:sustainability_report
|
https://www.novonordisk.com/sustainability.html
|
|
gptkbp:website
|
https://www.novonordisk.com/
|
|
gptkbp:bfsParent
|
gptkb:Glooko
gptkb:Helge_Lund
gptkb:Glooko_Inc.
gptkb:Gladsaxe,_Denmark
gptkb:NOVN
|
|
gptkbp:bfsLayer
|
5
|